TD01-BVL5

TD01-BVL5 is a first-in-class small molecule inhibitor of the disulfide bond formation protein A (DsbA) in *Acinetobacter baumannii*. Developed through a strategic collaboration between BioVersys and TandemAI using AI-driven drug discovery platforms, the compound is designed to address the critical need for new treatments against Carbapenem-resistant *Acinetobacter baumannii* (CRAB). DsbA is a periplasmic enzyme essential for the oxidative folding of numerous virulence factors and proteins involved in antibiotic resistance mechanisms. By selectively inhibiting DsbA, TD01-BVL5 impairs the bacterial ability to maintain structural integrity and secrete toxins, effectively disarming the pathogen and potentially re-sensitizing it to standard-of-care antibiotics. This anti-virulence mechanism offers a differentiated approach from traditional bactericidal or bacteriostatic agents, aiming to reduce the evolutionary pressure for resistance.